Anti-PD-1/PD-L1 agent
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-PD-1/PD-L1 agent, covering 2025-08-29 to 2025-08-29. Get the full timeline:
Most recent: Clinical Trial Update: Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer [Phase 2]